-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Downgrades Acumen Pharmaceuticals to Neutral, Lowers Price Target to $1

Benzinga·10/30/2026 20:34:46
Listen to the news
Citigroup analyst Geoff Meacham downgrades Acumen Pharmaceuticals (NASDAQ:ABOS) from Buy to Neutral and lowers the price target from $5 to $1.